Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2012.30.4_suppl.199
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Cost-Effectiveness of FOLFIRINOX for First-Line Treatment of Metastatic Pancreatic Cancer

Current Oncology
Oncology
2013English

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Journal of Oncology
Oncology
2020English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Pin40 - Cost-Effectiveness of First-Line Treatment for Invasive Aspergilosis in Colombia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

First-Line Treatment of Metastatic Lung Cancer—New Developments

Oncology & Hematology Review (US)
2008English

Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer

Current Oncology
Oncology
2019English

Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore

International Journal of Technology Assessment in Health Care
Health Policy
2019English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy